FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients
On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...
Cancer Therapy Advisor15h
FDA Approves Datroway for Advanced HR+, HER2- Breast Cancer
The FDA has approved Datroway (datopotamab deruxtecan) to treat adults with unresectable or metastatic, HR+, HER2- breast cancer who have received prior endocrine therapy and chemotherapy.
AstraZeneca’s Strategic Positioning and Datroway Approval Drive Buy Rating Amidst Evolving Breast Cancer Treatment Landscape
Analyst Andrew Berens of Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of ...
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
The FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs ...
DATROWAY® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
DATROWAY Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer ...
Healio1d
FDA approves Datroway for advanced breast cancer
The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication ...
InnovationRx: The Impact Of Trump’s Withdrawal From The WHO And His Other Healthcare Orders
Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA approved.
WebMD2h
FDA Approves New Treatment for Advanced Breast Cancer
The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the body or cannot be surgically removed.
BioSpace1d
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
BioPharma Dive1d
AstraZeneca, Daiichi’s Enhertu successor gets first FDA OK in breast cancer
The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...
Pharm Exec1d
FDA Approves AstraZeneca, Daiichi Sankyo’s Datroway for Previously Untreated Unresectable, Metastatic HR-Positive, HER2-Negative Breast Cancer
Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant ...
FiercePharma4d
Datroway, 2nd ADC from AstraZeneca-Daiichi collab, wins first FDA nod in breast cancer
Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the ...